A Scottish bioscience company, iGii has agreed a multi-million-pound deal with health monitoring company Prymexa to develop a toolkit that detects signs of perimenopause – the phase before the menopause.
A lack of awareness and monitoring can lead to misdiagnosis and missed opportunities for early intervention. Early identification of perimenopause, through the Stirling-based firm’s Gii sensor allows for more personalised advice, treatment and support from medical professionals.
The toolkit will look at various monitoring options, including wearable devices and sensors, to enable simple and affordable at-home monitoring that can be closely tracked by a medical professional.
Jean-Christophe Granier, CEO at iGii, said: “This project with Prymexa highlights the real value and potential of Gii and we look forward to working with them to positively impact the lives of those going through the perimenopause period.”
Sara Pardoe, CEO at Prymexa, said: “Menopause receives a fraction of the investment compared to other medical fields, yet half the population will experience it and demand for effective management solutions is growing exponentially.
“Our research aims to bring individuals closer to a simple, clear understanding of their menopause journey and how to best manage it.”
